In addition, TTK, CDC25A, and ESPL1 showed higher expression in cancers with late stage and higher tumour grade, compared with early stage and lower tumour grade (P < 0.05, Figures 8(a) and 8(b)). This evidence concerns the gene CDC25A and neoplasm.